Anzeige
Mehr »
Login
Sonntag, 13.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
Angehender Nickelproduzent mit 439 Mio. $ Gewinn pro Jahr!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JKVH ISIN: IE00B56GVS15 Ticker-Symbol: 8AK 
Tradegate
11.06.21
11:53 Uhr
20,800 Euro
0,000
0,00 %
1-Jahres-Chart
ALKERMES PLC Chart 1 Jahr
5-Tage-Chart
ALKERMES PLC 5-Tage-Chart
RealtimeGeldBriefZeit
20,40021,00012.06.
20,40021,00011.06.

Aktuelle News zur ALKERMES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.06.Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting201- Updated Data From ARTISTRY Clinical Program Highlight Anti-Tumor Activity as Monotherapy and in Combination With Pembrolizumab - - Data Support Advancement of Regulatory Strategy...
► Artikel lesen
04.06.Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference251DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare...
► Artikel lesen
02.06.Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More7
ALKERMES Aktie jetzt für 0€ handeln
02.06.Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved1
02.06.FDA approves Alkermes' Lybalvi for schizophrenia and bipolar I disorder1
01.06.Bouncing back from FDA rejection, Alkermes psychiatric drug wins approval1
01.06.Alkermes' schizophrenia drug Lybalvi picks up FDA nod, and a showdown with Eli Lilly's Zyprexa awaits1
01.06.Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med-
01.06.Alkermes wins FDA nod for combo med with antipsychotic olanzapine - this time without the weight gain red flags2
01.06.Alkermes schizophrenia drug gets U.S. FDA nod3
01.06.Alkermes plc. - 8-K, Current Report-
01.06.Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder329-- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain -- -- Commercial Launch Planned for Fourth Quarter 2021 -- -- Company to Host...
► Artikel lesen
31.05.The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes18
28.05.Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting322- Webcast to be Held at 4:00 p.m. ET on Friday, June 4 - DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call...
► Artikel lesen
20.05.Alkermes plc. - 8-K, Current Report1
20.05.Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors622DUBLIN, May 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva, to the company's Board of Directors ("Board")....
► Artikel lesen
13.05.Alkermes Announces 2021 Alkermes Inspiration Grants Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer147- Competitive Grants Program Application Period to Begin on May 20, 2021 - DUBLIN, May 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will begin...
► Artikel lesen
07.05.Why Shares of Alkermes Rose 18% Last Month3
05.05.Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference1.374DUBLIN, May 5, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference...
► Artikel lesen
03.05.Activist-investor target Alkermes clears Alex Denner's Sarissa Capital to fill board seat1
Seite:  Weiter >>
109 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1